Clinical Trial Update: A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of rituximab for debilitating fibrosing skin disorders, including localized scleroderma and eosinophilic fasciitis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Fasciitis
• Localized Scleroderma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) | Phase 2 | Status: COMPLETED